Vertex Pharmaceuticals Stock Falls After Mixed Phase 2 Trial Results
Vertex Pharmaceuticals stock fell after mixed Phase 2 trial results for its lumbosacral radiculopathy drug, suzetrigine. While the drug reduced pain, the placebo group showed similar improvement, raising questions about its efficacy.
Vertex Pharmaceuticals Stock Falls After Mixed Phase 2 Trial Results Read More »